Skip to main content
. 2020 Sep 15;4(18):4417–4429. doi: 10.1182/bloodadvances.2020002001

Figure 1.

Figure 1.

Drug screening pipeline and selected compounds. (A) The pipeline used to select compounds for t(6;11) cell lines: 1280 compounds were tested in ML-2 cells; 104 active drugs were tested in SHI-1; 93 active drugs were screened in the t(5;17) cell line HL60; and 20 nonactive drugs were tested in the t(9;11) cell lines THP-1 and NOMO-1. The 10 resulting compounds were considered selective for t(6;11)AML. Drug treatment was performed in triplicate, and compounds were considered active when cell viability was reduced to at least 60%. (B) Cell death (annexin V+, PI+, and annexin V+/PI+) induced by FLUS and TDZ in SHI-1 cells 24 and 48 hours after treatment (n = 3), relative to the DMSO value. (C) Colony-forming assay performed on viable SHI-1 cells seeded 24 hours after FLUS or TDZ treatment (n = 3). Data are the mean ± SEM. *P < .05; **P < .01; ***P < .001; ****P < .0001.